Selecta Biosciences Receives a Buy from Mizuho Securities

By Ryan Adsit

In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Selecta Biosciences (NASDAQ: SELB), with a price target of $30. The company’s shares closed yesterday at $9.36, close to its 52-week low of $7.95.

Yang said:

“We believe the expected phase 3 trial including 6 monthly combination doses of SEL-212 has a high likelihood of success.”

According to TipRanks.com, Yang is a 5-star analyst with an average return of 21.5% and a 50.1% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Alder Biopharmaceuticals, and Audentes Therapeutics.

Selecta Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $30.

Based on Selecta Biosciences’ latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $17K and GAAP net loss of $19.54 million. In comparison, last year the company earned revenue of $137K and had a GAAP net loss of $15.13 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The firm produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation.